ArriVent Biopharma Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

AVBP$13.49-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2023 and 2022


· · December 31,
· 2023 · 2022
Assets · ·
Current assets: · ·
Cash and cash equivalents	$150,389	$163,372
Prepaid expenses and other current assets	9,579	19,250
Total current assets	159,968	182,622
Right of use assets – operating leases	291	139
Deferred offering costs	2,732	—
Other assets	107	72
Total assets	$163,098	$182,833

Liabilities, Convertible Preferred Stock and Stockholders’ (Deficit)
Current liabilities:
Accounts payable	$4,532	$3,094
Accrued expenses	6,952	5,138
Operating lease liabilities	140	128
Total current liabilities	11,624	8,360
Operating lease liabilities	177	11
Total liabilities	11,801	8,371

Commitments and contingencies (Note 7)

Series A convertible preferred stock $0.0001 par value, 150,000,000 shares authorized; 150,000,000 shares issued and outstanding at December 31, 2023 and 2022; liquidation preference of $150,000 at December 31, 2023	149,865	149,865
Series B convertible preferred stock $0.0001 par value, 147,619,034 shares authorized; 147,619,034 and 104,761,894 shares issued and outstanding at December 31, 2023 and 2022, respectively; liquidation preference of $155,000 at December 31, 2023	154,625	109,706

Stockholders’ (deficit):
Common stock $0.0001 par value, 368,600,500 shares authorized; 2,745,480 and 2,597,738 shares issued and outstanding at December 31, 2023 and 2022, respectively	—	—
Additional paid-in capital	4,652	3,403
Accumulated deficit	(157,845)	(88,512)
Total stockholders’ (deficit)	(153,193)	(85,109)
Total liabilities, convertible preferred stock and stockholders’ (deficit)	$163,098	$182,833

STATEMENTS OF OPERATIONS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.